RxDoctor Payments Data

Francisco Carreras-Miranda, MD

General Practice · Caguas, PRNPI 1659628089

Payments from drug & device makers

$2,104in general payments, 2019–2025

Across 103 payments — averaging $20.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$631
  • Novo Nordisk$439
  • Amarin Pharma, Inc.$277
  • Bayer$270
  • Ironshore Pharmaceuticals Inc.$63
  • Merck$61
  • plus $363 from 13 others

What the payments were for

  • Food & beverage$2,104100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,104 in reported general payments places this provider in the 90th percentile of 3,586 general practice providers in Puerto Rico.

See all general practice providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$113,837
Medicare patients
407
Services billed
1,478

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide105$144,039
FarxigaDapagliflozin Propanediol70$82,380
EliquisApixaban38$52,443
RybelsusSemaglutide22$48,875
JardianceEmpagliflozin37$45,005
MounjaroTirzepatide34$37,890
EntrestoSacubitril/Valsartan36$37,178
TrulicityDulaglutide19$34,835
Breztri AerosphereBudesonide/Glycopyr/Formoterol24$33,600
Trelegy ElliptaFluticasone/Umeclidin/Vilanter34$27,823
XareltoRivaroxaban34$26,682
VascepaIcosapent Ethyl13$11,416
SymbicortBudesonide/Formoterol Fumarate25$10,403
Tresiba Flextouch U-100Insulin Degludec13$7,628
InvokanaCanagliflozin13$7,453

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$439$192,914127 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$32$126,383119 claims
PfizerEliquis$50$52,44338 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,586 general practice providers in Puerto Rico.

Other general practice in Caguas

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →